Brandon K Collins

Discovery of potent, selective chymase inhibitors via fragment linking strategies.

Daniel R. Albaugh, Ming-Hong Hao, M. Hao, 2013, Journal of medicinal chemistry.

Indole Inhibitors of MMP-13 for Arthritic Disorders

Qiang Zhang, I. Muegge, J. Proudfoot, 2021, ACS omega.

Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.

Xiang Li, Ingo Muegge, Hani S. Zaher, 2011, Journal of medicinal chemistry.

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.

R. D. Dyer, Adam R. Johnson, K. Aston, 2010, Bioorganic & medicinal chemistry letters.

Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.

Zhaoming Xiong, B. Farmer, Qiang Zhang, 2009, Bioorganic & medicinal chemistry letters.

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.

Dean M. Messing, J. Collins, Michelle A. Schmidt, 2016, Journal of medicinal chemistry.

SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.

J. Proudfoot, N. Moss, N. Farrow, 2010, Bioorganic & medicinal chemistry letters.